GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells With Squalene Adjuvant

Two of the world’s largest vaccine manufacturers are using DNA technology, insect cells and a squalene adjuvant, AS03, as the basis to develop a COVID-19 vaccine together. GlaxoSmithKline (GSK) and Sanofi Pasteur are partners in the enterprise, with clinical trials set to begin in 2020. The squalene adjuvant is aluminum-based and is designed to induce a higher immune response through an enhanced inflammatory process. While aluminum is currently in other vaccines such as hepatitis...

Read the Full Article for Free!

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy

Subscribe for FREE to the #1 Natural Health Newsletter or Login for Instant Access

Unlock censored health information that Google doesn't want you to read

Keep your privacy secure — we are one of the few websites that have banned all Google and Facebook scripts to help stop their surveillance capitalism

Get access to all of Dr. Mercola's health articles, E-books and special reports